Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Sarcoma 1Myeloid 1Lymphoid 1Gastrointestinal 1CNS 1

Conditions

Sarcoma, Myeloid 1Myeloproliferative Disorders 1Leukemia, Myeloid, Acute 1Blast Crisis 1

Interventions

fludarabine 30Specimen Handling 28Cyclophosphamide 27Azacitidine 23venetoclax 22fludarabine phosphate 22Biopsy 22ruxolitinib 18Whole-Body Irradiation 17Cytarabine 17Mycophenolic Acid 16Busulfan 16asciminib 15Tacrolimus 15Melphalan 14Injections 12Decitabine 12decitabine and cedazuridine drug combination 11X-Rays 11Magnetic Resonance Spectroscopy 11Stem Cell Transplantation 10Granulocyte Colony-Stimulating Factor 10Sirolimus 9Peripheral Blood Stem Cell Transplantation 9Cyclosporine 9Thiotepa 8Filgrastim 8nilotinib 7Imatinib Mesylate 7Phantoms, Imaging 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Razoxane × Myeloid × 90 days × Clear all
NCT03589729 2026-05-22

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

M.D. Anderson Cancer Center

Phase 2 Recruiting
100 enrolled
MyeloidOther hematologic neoplasmSarcoma

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡